At present, this vaccine has obtained the national patent, proved to be safe and effective, and will be mass-produced. It can be said that this vaccine has no side effects and is safe. The level of scientific research in China is constantly developing. We should keep a good attitude, be proud of the research results of epidemic situation in China, and be proud of our epidemic prevention workers!
Liu Jingzhen, Party Secretary and Chairman of China Pharmaceutical Group Co., Ltd. said that after the third phase of international clinical trials, inactivated vaccines can enter the approval process. It is expected that the vaccine will be available at the end of February this year, and the output of this batch of vaccines in Beijing can reach10.20 billion. Even in Wuhan, the annual output can reach 1 100 million doses. According to the safety of the vaccine, the immune, epidemic prevention and safety of the vaccine were achieved in the clinical trial evaluation of eating more. The safety and immunogenicity of the vaccine were verified by the standard.
Through the second phase clinical trial and the first phase clinical trial, the safety and immunogenicity of the vaccine in a wider range of people have been improved. It provides further proof that it can be consulted all over the world and the information is completely open. This means that China's medical level and intellectual property system are confident enough.
About the protection rate of vaccines. Liu Jingzhen, secretary of the Party Committee and chairman of China Pharmaceutical Group Co., Ltd., said that the protection rate of the vaccine after one injection is about 97%, because the antibody production is slow and grows slowly like a curve. So it usually takes about half a month to reach the level of resistance to starlight virus. If two shots of vaccine are given, the protection rate can even reach 100%.